BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12085228)

  • 1. Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2.
    Clark PA; Llanos S; Peters G
    Oncogene; 2002 Jul; 21(29):4498-507. PubMed ID: 12085228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.
    Xirodimas DP; Chisholm J; Desterro JM; Lane DP; Hay RT
    FEBS Lett; 2002 Sep; 528(1-3):207-11. PubMed ID: 12297306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the molecular basis of Arf and Hdm2 interactions.
    Bothner B; Lewis WS; DiGiammarino EL; Weber JD; Bothner SJ; Kriwacki RW
    J Mol Biol; 2001 Nov; 314(2):263-77. PubMed ID: 11718560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization.
    Rizos H; Darmanian AP; Mann GJ; Kefford RF
    Oncogene; 2000 Jun; 19(26):2978-85. PubMed ID: 10871849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
    Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.
    Zhang Y; Xiong Y; Yarbrough WG
    Cell; 1998 Mar; 92(6):725-34. PubMed ID: 9529249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
    Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
    Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.
    Yin Y; Stephen CW; Luciani MG; Fåhraeus R
    Nat Cell Biol; 2002 Jun; 4(6):462-7. PubMed ID: 12032546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus.
    Llanos S; Clark PA; Rowe J; Peters G
    Nat Cell Biol; 2001 May; 3(5):445-52. PubMed ID: 11331871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
    Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
    Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
    Stott FJ; Bates S; James MC; McConnell BB; Starborg M; Brookes S; Palmero I; Ryan K; Hara E; Vousden KH; Peters G
    EMBO J; 1998 Sep; 17(17):5001-14. PubMed ID: 9724636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARF function does not require p53 stabilization or Mdm2 relocalization.
    Korgaonkar C; Zhao L; Modestou M; Quelle DE
    Mol Cell Biol; 2002 Jan; 22(1):196-206. PubMed ID: 11739734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts.
    Khan S; Guevara C; Fujii G; Parry D
    Oncogene; 2004 Aug; 23(36):6040-6. PubMed ID: 15195142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
    Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
    Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53.
    Jackson MW; Agarwal MK; Agarwal ML; Agarwal A; Stanhope-Baker P; Williams BR; Stark GR
    Oncogene; 2004 May; 23(25):4477-87. PubMed ID: 15064747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.
    Fulci G; Labuhn M; Maier D; Lachat Y; Hausmann O; Hegi ME; Janzer RC; Merlo A; Van Meir EG
    Oncogene; 2000 Aug; 19(33):3816-22. PubMed ID: 10949938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
    Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
    J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
    Kamijo T; Weber JD; Zambetti G; Zindy F; Roussel MF; Sherr CJ
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8292-7. PubMed ID: 9653180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypophosphorylation of Mdm2 augments p53 stability.
    Blattner C; Hay T; Meek DW; Lane DP
    Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.